J&J backs out of RSV vaccine race with rivals Pfizer and GSK
J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV vaccines in the last month.
New York identifies ‘disadvantaged communities’ that will receive extra climate funding
The communities in New York City are located in northern Manhattan and the Bronx, as well as central Brooklyn and across the coastlines.
House lawmakers tear into top bank regulators in second hearing this week on SVB collapse
“We need competent financial supervisors. But Congress can’t legislate competence,” House Financial Services chairman Rep. Patrick McHenry told regulators.
Amid inflation, nearly half of parents financially support their adult children, but ‘it has to go both ways,’ economist warns
On average, parents who financially support grown children give them $1,400 a month for expenses such as food, rent, cell phones and car insurance.
Carl Icahn wants to bring back Illumina’s ex-CEO ‘immediately’ as proxy fight intensifies
Icahn said Illumina should bring back former CEO Jay Flatley, saying current management is making the mistake of holding onto the $7.1 billion Grail deal.
Citi upgrades Lululemon shares to buy, citing strong brand momentum
Citi upgraded Lululemon shares to buy from neutral, saying that it has more than 37% upside as its brand momentum continues.
As climate change intensifies extreme weather, NOAA looks to startups to help improve its forecasts
NOAA is exploring buying data from startups such as Tomorrow.io and Saildrone to help it improve its weather forecasting.
FDA approves over-the-counter sales of lifesaving opioid overdose treatment Narcan nasal spray
The FDA’s decision means people will be able to buy the 4mg nasal spray without a prescription in supermarkets, convenience stores and vending machines.
‘Light at the end of the tunnel:’ Some analysts see improvements ahead for Micron after tough quarter
Despite Micron’s disappointing second fiscal quarter results amid a downturn in the semiconductor space, several analysts are optimistic it will soon recover.
UBS says investors should sell this footwear retailer as it will struggle in a recession
Analyst Jay Sole downgraded the stock to sell from neutral and cut his price target to $30 from $36, implying downside of 25% from Tuesday’s close.
